Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Drug-induced lupus: Possible mechanisms and their implications for prediction of which new drugs may induce lupus

References to Primarv Literature

• WALLACE DJ, DUBOIS EL: Dubois' Lupus Erythematosus. 3rd Edition, Lea & Febiger, Philadelphia (1987). A good description of the clinical characteristics of DIL.
   Google Scholar
• HOFFMAN BJ: Sensitivity to sulfadiazine resembling acute lupus erythematosus. Arch. Dermatol. Syph. (1945) 51:190–192.
   Google Scholar
• ADAMS LE, HESS EV: Drug-related lupus. Drug Safety •(1991) 6(6):431–449. Another review of DIL.
   Google Scholar
• PRICE EJ, VENABLES PJ: Drug-induced lupus. Drug Safety •(1995) 12(4):283–290. Another review of DIL.
   Google Scholar
• YUNG RL, RICHARDSON BC: Drug-induced lupus. Rheu-matic Diseases Clinics of North America (1994) 20(1):61–86. Another review of DIL.
   Google Scholar
• HENNINGSEN NC, CEDERBERG A, HANSON A, JOHANSSON BW: Effects of long-term treatment with procaine amide. Ada Med. Scand. (1975) 198:475–482,
   PubMed Web of Science ®Google Scholar
• WOOSLEY RL, DRAYER DE, REIDENBERG MM et al.: Effect of acetylator phenotype on the rate at which procai-namide induces antinuclear antibodies and the lupus syndrome. New Engl. J. Med. (1978) 298:1157–1159.
   PubMed Web of Science ®Google Scholar
• FRITZLER MJ, TAN EM: Antibodies to histones in drug-in-duced and idiopathic lupus erythematosus. j Clin. In-vest. (1978) 62:560–567.
   PubMed Web of Science ®Google Scholar
• CAMERON HA, RAMSAY LE: The lupus syndrome induced by hydralazine: a common complication with low dose therapy. Br. Med. J. (1984) 289:410–412.
   PubMed Web of Science ®Google Scholar
• ZARRABI MH, ZUCKER S, MILLER F et al.: Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann. Intern. Med. (1979) 91(2):194–199.
   PubMed Web of Science ®Google Scholar
• LIELICRAP DP, PINTO M, BENFORD K, FORD PM, FORD S: Heterogeneity of laboratory test results for antiphos-pholipid antibodies in patients treated with chloropro-mazine or other phenothiazines. Am. J. Clin. Pathol. (1990) 93:771–775.
   PubMed Web of Science ®Google Scholar
• PETERS RL, EDMONDSON HA, MIKKELSEN WP, TATTER D: Tetracycline-induced fatty liver in nonpregnant pa-tients. A report of six cases. Am. J. Surgery (1967) 113(5):622–632.
   PubMed Web of Science ®Google Scholar
• GOUGH A, CHAPMAN S, WAGSTAFF K, EMERY P, ELIAS E: Minocycline induced autoimmune hepatitis and sys-temic lupus erythematosus-like syndrome. Br. Medi I (1996) 312:169–172.
   PubMed Web of Science ®Google Scholar
• RAFTERY EB, DENMAN AM: Systemic lupus erythematosus syndrome induced by practoloL Br. Med. J. (1973) 2:452–455.
   Google Scholar
• RONNBLOM LE, ALM GV, OBERG KE: Autoinnnunity after alpha-interferon therapy for malignant cardnoid tu-mors. Ann. Intern. Med. (1991) 115:178–183.
   PubMed Web of Science ®Google Scholar
• GRANINGER WB, HASSFELD W, PESAU BB eta/.: Induction of systemic lupus erythematosus by interferon-gamma In a patient with rheumatoid arthritis. J. Rheumatology (1991) 18(10):1621–1622.
   Google Scholar
• VIAL T, DESCOTES J: Imxnune-mediated side-effects of cytokines in humans. Toxicol. (1995) 105:31–57.
   PubMed Web of Science ®Google Scholar
• HANDWERGER BS, RUS V, DA SILVA L, VIA CS: The role of cytokines in the immunopathogenesis of lupus. Springer Semin. Immunopatha (1994) 16:153–180.
   PubMed Web of Science ®Google Scholar
• HORWITZ DA, JACOB CO: The cytolkine network in the pathogenesis of systemic lupus erythematosus and pos-sible therapeutic implications. Springer Semin. Immu-nopathol. (1994) 16:181–200.
   PubMed Web of Science ®Google Scholar
• MALINOW MR, BARDANA EJ, PIROFSKY B, CRAIG S, MCLAUGHLIN P: Systemic lupus erythematosus-like syn-drome in monkeys fed alfalfa sprouts: role of a non-protein amino add. Science (1982) 216:415–417.
   PubMed Web of Science ®Google Scholar
• MALINOW MR, BARDANA EJ, Jr., GOODNIGHT SH, Jr.:Pancytopenia during ingestion of alfalfa seeds [letter]. Lancet (1981) 1(8220 Pt. 1):615.
   Google Scholar
• ROBERTS JL, HAYASHI JA: Exacerbation of SLE associatedwith alfalfa ingestion [letter]. New Engl. J. Med. (1983) 308(22):1361.
   PubMed Web of Science ®Google Scholar
• TABUENCA JM: Toxic-allergic syndrome caused by in-gestion of rapeseed oil denatured with aniline. Lancet (1981) 2(8246):567–568,
   PubMed Web of Science ®Google Scholar
• KILBOURNE EM, RIGAU PEREZ J, HEATH CW et al.: Clinical epidemiology of toxic-oil syndrome: manifestations of a new illness. New Engl. J. Med. (1983) 309(23):1408–1414.
   PubMed Web of Science ®Google Scholar
• BELL SA, HOBBS MV, RUBIN RL: Isotype-restricted hy-perimmunity in a murine model of the toxic oil syn-drome. J. Immunology (1992) 148(11):3369–3376.
   PubMed Web of Science ®Google Scholar
• REIDENBERG MM: Aromatic amines and the pathogenesis of lupus erythematosus. Am. J. Med. (1983) 75:1037–1042.
   PubMed Web of Science ®Google Scholar
• UETRECI IT JP: Mechanism of drug-induced lupus. Chem. Res. Toxicol. (1988) 1(3):133–143. First suggestion that reactive metabolites generated by leukocytes are responsible for DIL.
   Google Scholar
• NELSON SD, PEARSON PG: Covalent and noncovaknt interactions in acute lethal cell injury caused by chemi-cals. Ann. Rev. Pharmacol. Toxicol. (1990) 30:169–195.
   PubMed Web of Science ®Google Scholar
• POHL LR, SATOH H, CHRIST DD, ICENNA JG: The immu-nologic and metabolic basis of drug hypersensitivitks. Ann. Rev. Pharmacol (1988) 28:367–387.
   Google Scholar
• PARK BK, PIRMOHAMED M, Kit IERINGHAM NR: The roleof cytochrome P450 enzymes in hepatic and extrahepa-tic human drug toxicity. Pharmacol. Ther. (1995) 68(3):385–424.
   PubMed Web of Science ®Google Scholar
• WEISS SJ: Tissue destruction by neutrophils. New Engl. J.Med. (1989) 320(6):365–376.
   PubMed Web of Science ®Google Scholar
• UETRECHT JP: Drug metabolism by leukocytes, its role in drug-induced lupus and other idiosyncratic drug reactions. CRC Crit. Rev. Toxicol. (1990) 20(4):213–235. More recent review of reactive metabolites formed by leukocytes.
   Google Scholar
• UETRECHT JP: The role of leukocyte-generated metabo lites in the pathogenesis of idiosyncratic drug reactions. Drug Metab. Rev. (1992) 24(3):299–366. More recent review of reactive metabolites formed by leukocytes.
   Google Scholar
• GRIFFITHS ID, KANE SP: Sulphasalazine-induced lupus syndrome in ulcerative colitis. Br. Med. J. (1977) 2:1188–1189.
   PubMed Web of Science ®Google Scholar
• VANHEULE BA, CARSWELL F: Sulphasalazine-induced systemic lupus erythematosus in a child. Eur.J. Pediatr. (1983) 140:66–68.
   PubMed Web of Science ®Google Scholar
• CRIBB AE, SPIELBERG SP: Hepatic microsomal metabo-lism of sulfamethoxazole to the hydroxylamine. Drug Metab. Dispos. (1990) 18(5):784–787.
   PubMed Web of Science ®Google Scholar
• CRIBB AE, MILLER M, TESORO A, SPIELBERG SP: Peroxi-dase-dependent oxidation of sulfonamides by mono-cytes and neutrophils from humans and dogs. Mol. Pharmacol. (1990) 38:744–751.
   PubMed Web of Science ®Google Scholar
• CRIBB AE, SPIELBERG SP: Suliamethoxazole is metabo-lised to the hydroxylamine in humans. Clin. Pharmacol. Ther. (1992) 51:522–526.
   PubMed Web of Science ®Google Scholar
• UETRECHT JP, SWEETMAN BJ, WOOSLEY RI, OATES JA:Metabolism of procainamide to a hydroxylamine by rat and human hepatic microsomes. Drug Metab. Disp. (1984) 12(1):77–81.
   PubMed Web of Science ®Google Scholar
• UETRECHT J, ZAHID N, RUBIN R: Metabolism of procai-namide to a hydroxylamine by human neutrophils and mononuclear leukocytes. Chem. Res. Toxicol. (1988) 1(1):74–78.
   PubMed Web of Science ®Google Scholar
• GARCIA-MORTEO O, MALDONADO-COCCO JA: Lupus-like syndrome during treatment with nomifensine. Arthritis Rheum, (1983) 26:936.
   PubMed Web of Science ®Google Scholar
• WILSON JD, BULLOCK JY, SUTHERLAND DC, MAIN C, O'BRIEN KP: Antinuclear antibodies in patients receiv-ing non-practolol beta-blockers. Br. Med. J (1978) 1:14–16.
   PubMed Web of Science ®Google Scholar
• BOOTH RJ, WILSON JD, BULLOCK JY: ll-Adrenergic-re-ceptor blockers and antinuclear antibodies in hyper-tension. Clin. Pharmacol. Ther. (1982) 31(9:555–558.
   PubMedGoogle Scholar
• MCCRAKEN M, BENSON EA, HICICLING : Systemic lupus erythematosus induced by aminog,lutethirnide. Br. Med. J (1980) 281:1254.
   PubMed Web of Science ®Google Scholar
• PENT MT, GANAPATHY S, HOLDSWORTH CD, CHANNER KC: Mesalazine induced lupus-like syndrome. Br. Med. J (1992) 305(6846):159.
   PubMed Web of Science ®Google Scholar
• LIU ZC, MCCLELLAND RA, UETRECHT JP: Oxidation of 5-aminosalicylic acid by hypochlorous add to a reactive metabolite: possible role in the treatment of inflamma-tory bowel disease. Drug Metab. Dispos. (1995) 23(2):246–250.
   PubMed Web of Science ®Google Scholar
• VANDERSTEEN PR, JORDON RE: Dermatitis herpetifor-mis with discoid lupus erythematosus: occurrence of sulfone-induced discoid lupus erythematosus. Arch. Dermatol. (1974) 110:95–98.
   PubMed Web of Science ®Google Scholar
• UETRECHT J, ZAHID N, SHEAR NH, BIGGAR WD: Metabo-lism of dapsone to a hydroxylamine by human neutro-phils and mononuclear cells. J. Pharmacol. Exp. Ther. (1988) 245(1):274–279.
   PubMed Web of Science ®Google Scholar
• RADOMSKI JL: The primary aromatic amines: their bio-logical properties and structure-activity relationships. Ann. Rev. Pharmacol. Toxicol. (1979) 19:129–157.
   PubMed Web of Science ®Google Scholar
• HOFSTRA AH, MATASSA LC, UETRECHT JP: Metabolism of hydralazine by activated neutrophils: implications for hydralazine-induced lupus. J. Rheumatol. (1991) 18(11):1673–1680.
   PubMed Web of Science ®Google Scholar
• HOFSTRA A, UETRECHT JP: Metabolism of hydralazine to a reactive intermediate by the oxidizing system of activated leukocytes. Chemico-Biol. Interact. (1 9 9 3) 89:183–196.
   Google Scholar
• ROTHFIELD NF, BIERER WE, GARFIELD JW: Isoniazid Induction of antinuclear antibodies: a prospective study. Ann. Intern. Med. (1978) 88(5):650–652,
   PubMed Web of Science ®Google Scholar
• HOFSTRA AH, ANGELA LI-MULLER SM, UETRECHT JP: Metabolism of isoniazid by activated leukocytes: possi-ble role in drug-induced lupus. DrugMetab.Dispos. (1992) 20(2):205–210.
   PubMed Web of Science ®Google Scholar
• REIDENBERG MM, DURANT PJ, HARRIS RA et al.: Lupuserythematosus-like disease due to hydrazine. Am.J. Med. (1983) 75:365–370.
   PubMed Web of Science ®Google Scholar
• COLEMAN JW, FOSTER AL, YEUNG JHK, PARK BK: Drug-protein conjugates XV: a study of the disposition of D-penicillamine in the rat and its relationship to immu-nogenicity. Biochem. Pharmacol. (1988) 37(4):737–742.
   PubMed Web of Science ®Google Scholar
• JOYCE DA: In vitro mechanism of oxidation of D-penidliamine in plasma.]. Pharrn. Sci. (1991) 80(3):289–292.
   Google Scholar
• JAFFE IA: induction of auto-immune syndromes by penicillamine therapy in rheumatoid arthritis and other diseases. Springer Semin. Immunopathol. (1981) 4:193–207.
   PubMed Web of Science ®Google Scholar
• CHALMERS A, THOMPSON D, STEIN HE, REID G, PA! LES-SON AC: Systemic lupus erythematosus during penidl-lamine therapy for rheumatoid arthritis. Ann. Intern. Med. (1982) 97(5):659–663.
   PubMed Web of Science ®Google Scholar
• ENZENAUER RJ, WEST SG, RUBIN RL: duced lupus erythematosus. Arthritis Rheum. (1990) 33(10):1582–1585.
   PubMedGoogle Scholar
• HARKCOM TM, CONN DL, HOLLEY KE: D-Penicillarnine and lupus erythematosus-like syndrome. Ann. Intern. Med. (1978) 89(6):1012.
   PubMed Web of Science ®Google Scholar
• DONKER AJ, VENUTO RC, VLADUTIU AO, BRENTJENS JR, AND1XES GA: Effects of prolonged administration of D-penicillamine or captopril in various strains of rats. din. Immunol. Immunopath. (1984) 30:142-155. The first description of this useful animal model of DIL.
   Google Scholar
• REIDENBERG MM, CASE DB, DRAYER DE, BETS S, LORENZO B: Development of antinudear antibody in patients treated with high doses of captopriL Arthritis Rheum. (1984) 27(5):579–581.
   Google Scholar
• PATRI P, NIGRO A, REBORA A: Lupus erythematosus-likeeruption from captopriL Acta. Derm. Venereol. (1985) 65:447–448.
   PubMed Web of Science ®Google Scholar
• AMRHEIN JA, KENNY FM, ROSS D: Granulocytopenia, lupus-like syndrome, and other complications of propylthiouracil therapy. J. Pediatr. (1970) 76(1):54–63.
   PubMed Web of Science ®Google Scholar
• BERKMAN EM, ORLIN JB, WOLFSDORF J: An anti-neutro-phil antibody associated with a propylthiouracii-in-duced lupus-like syndrome. Transfusion (1983) 23(2):135438.
   Google Scholar
• TAKUWA N, KOJIMA I, OGATA E: Lupus-like syndrome -a rare complication in thionamide treatment for Graves' disease. Endocrinol.Japan (1981) 28(5):663–667.
   PubMedGoogle Scholar
• KURTZ MD: Migratory polyarthritis occurring with methimazole therapy. NYS J. Med. (1968) 68:2810–2811.
   Google Scholar
• AUCOIN DP, PETERSON ME, HURVITZ Al et al.: Propylthiouracil-induced immune-mediated disease in the cat. J. Pharmacol. Exp. Ther. (1985) 234(1):13–18.
   PubMed Web of Science ®Google Scholar
• AUCOIN DP, RUBIN RI, PETERSON ME et al.: Dose-de-pendent induction of anti-native DNA antibodies in cats by propylthiouracil. Arthritis Rheum. (1988) 31(5):688–692.
   PubMed Web of Science ®Google Scholar
• NEAL RA: Thiono-sulfur compounds. In: Bioactivation ofForeign Compounds. Anders MW (Ed.), Academic Press, London (1985):519–540.
   Google Scholar
• LEE E, MIKI Y, HOSOKAWA M, SAY° H, KARIYA K: Oxidative metabolism of propylthiouracil by peroxi-dases from rat bone marrow. Xenobiotica (1988) 18(10):1135–1142.
   PubMed Web of Science ®Google Scholar
• WALDHAUSER L, UETRECHT J: Oxidation of propylthiouracil to reactive metabolites by activated neutrophils: implications for agranulocytosis. Drug Metab. Dispos. (1991) 19(2):354–359.
   PubMed Web of Science ®Google Scholar
• MACHTEY I: Polyarthritis following propranoloL Arthri-tis Rheum. (1981) 24(3):568–569.
   Google Scholar
• ROWLAND K, YE0 WW, ELLIS SW et al.: inhibition ofCYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol Br. J. Clin. Pharmacol. (1994) 38:9–14.
   Google Scholar
• LAVIE CJ, BIUNDO J, QUINET RJ, WAXMAN J: Systemiclupus erythematosus (SLE) induced by quinidine. Arch. Intern. Med (1985) 145:446–448.
   PubMed Web of Science ®Google Scholar
• PIRMOHAMED M, KITTERINGHAM NR, GUENTHNER TM,BRECKENRIDGE AM, PARK BK: An investigation of the formation of cytotoxic, protein-reactive and stable me-tabolites from carbamazepine in vitro. Biochem. Phar-macol. (1992) 43(8):1675–1682.
   PubMed Web of Science ®Google Scholar
• UETRECHT J, ZAHID N: N-Chlorination of phenytoin bymyeloperoxidase to a reactive metabolite. Chem. Res. Toxicol. (1988) 1(3):148–151.
   PubMed Web of Science ®Google Scholar
• FURST SM, UETRECHT JP: Carbamazepine metabolism toa reactive intermediate by the myeloperoxidase system of activated neutrophRs. Blocher?) Pharmacol. (1993) 45(6):1267–1275.
   PubMed Web of Science ®Google Scholar
• VAN ZYL JM, BASSON K, KRIEGLER A, VAN DER WALT BJ:Activation of chloropromazine by myeloperoxidase system of the human neutrophiL Biochem. Pharmacol. (1990) 40(5):947–954.
   Web of Science ®Google Scholar
• PORTANOVA JP, RUBIN RLJOSLINt•FG, AGNELLO VD, TAN EM: Reactivity of anti-histone antibodies induced by procainamide and hydralazine. Clin. Immunol. Immu-nopathol. (1982) 25:67–79.
   PubMedGoogle Scholar
• CRAFT JE, RADDING JA, HARDING MW, BERNSTEIN RM, HARDIN JA: Autoantigenic histone epitopes: a compari-son between procainamide- and hydralazine-induced lupus. Arthritis Rheum. (1987) 30(6):689–694.
   PubMed Web of Science ®Google Scholar
• BURLINGAME RW, RUBIN RL: Drug-induced anti-historte autoantibodks display two patterns of reactivity with substructures of chromatin. J. Clin. Invest. (1991) 88:680–690.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ RS, STOLLAR BD: Origins of anti-DNA autoan-tibodies. j Clin. Invest. (1985) 75:321–327.
   PubMed Web of Science ®Google Scholar
• PORTANOVA JP, KOTZIN BL: Lupus-like autoimmunity in murine graft-versus host disease. In: Cellular Aspects of Autoimmuni (Concepts in Immunopathology; series). Cruse JM, Lewis RE, Jr. (Eds.), Karger, Basel (1988):119–140.
   Google Scholar
• VAN RAPPARD-VAN DER VEEN FM, KIESEL U, POELS L et al.: Further evidence against random polyclonal anti-body formation in mice with lupus-like graft-vs-host disease. J. Immunol. (1984) 132(4):1814–1820.
   Google Scholar
• SHLOMCHIK M, MASCELLI M, SHAN H et al.: Anti-DNA antibodies from autoimmune mice arise by clonal ex-pansion and somatic mutation. J. Exp. Med. (1990) 171(1):265–292.
   PubMed Web of Science ®Google Scholar
• BURLINGAME RW, BOEY ML, STARKEBAUM G, RUBIN RI: The central role of chromatin in autoimmune re-sponses to histones and DNA in systemic lupus erythe-matosus. J. Clin. Invest. (1994) 94(1):184–192.
   PubMed Web of Science ®Google Scholar
• SIM E, GILL ENV, SIM RB: Drugs that induce systemic lupus erythematosus inhibit complement component C4. Lancet (1984) 2:422–424.
   PubMed Web of Science ®Google Scholar
• SIM E, LAW SA: Hydralazine binds covalently to comple-ment component C4: different reactivity of C4A and C4B gene products. FEBS (1985) 184(2):323–327.
   PubMed Web of Science ®Google Scholar
• SIM E, STANLEY L, GILL EW, JONES A: Metabolites of procainamide and practolol inhibit complement com-ponents C3 and C4. Biochem. J. (1988) 251(2):323–326.
   PubMed Web of Science ®Google Scholar
• THOMAS TJ, MESSNER RP: Effects of lupus-inducing drugs on the B to Z transition of synthetic DNA. Arthritis Rheum. (1986) 29(5).638–645,
   PubMed Web of Science ®Google Scholar
• MONGEY AB, DONOVAN-BRAND R, THOMAS TJ, ADAMSLE, HESS EV: Serologic evaluation of patients receiving procainamide [see comments]. Arthritis Rheum. (1992) 35(2):219–223.
   PubMed Web of Science ®Google Scholar
• UETRECHT JP, WOOSLEY RI: Acetylator phenotype andlupus erythematosus. Clin. Pharmacokin. (1981) 6:118–134.
   PubMed Web of Science ®Google Scholar
• LAIIITA R, KLUGER J, DRAYER DE, KOFFLER D, REIDEN-BERG MM: Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainanaide. New Engl. J. Med. (1979) 301(25):1382–1385.
   PubMed Web of Science ®Google Scholar
• RODEN DM, REELE SB, HIGGINS SB, et al.: Antiarrhythmic efficacy, pharmaccskinetics and safety of N-acetylpro-cainamide in human subjects: comparison with procai-namide. Am. J. Cardiol. (1980) 46:463–468.
   Google Scholar
• KUBICKA-MURANYI M, GOEBELS R, GOEBEL C, LTETRECHT J, GLEICHMANN E: T Lymphocytes ignore procainarnide, but respond to its reactive metabolites in peritoneal cells: demonstration by the adoptive transfer popliteal lymph node assay. Toxicol. Appl. Pharmacol. (1993) 122:88-94. A description of the immune effects of a reactive metabolite of procainamide.
   Google Scholar
• GOLD EF, BEN-EFRAIM S, FAIVISEWITZ A, STEINER Z, KLAJMAN A: Experimental studies on the mechanism of induction of anti-nuclear antibodies by procainamide. Clin. Immunol. Immunopathol. (1977) 7:176–186.
   PubMedGoogle Scholar
• LEHMANN PV, FORSTHUBER T, MILLER A, SERCARZ EE: Spreading of T-cell autoimmunity to cryptic determi-nants of an autoantigen. Nature (1992) 358(6382).155–157.
   PubMed Web of Science ®Google Scholar
• LANZAVECCHIA A: How can cryptic epitopes trigger 9.autoimmunity. J. Exp. Med. (1995) 181:1945-1948.A clear but brief discussion of cryptic antigens.
   Google Scholar
• KUBICKA-MURANYI M, GRIEM P, LUBBEN B, ROTTMANN •N, LUHRMANN R, GLEICHMANN E: Mercuric-chloride-in-duced autoimmunity in mice involves up-regulated presentation by spleen cells of altered and unaltered nucleolar self antigen. Int. Arch. Allergy Immunol. (1995) 108:1-10. Mechanistic studies of DIL in an animal model.
   Google Scholar
• BELL SA, DU CLOS TW, KHURSIGARA G, PICAZO JJ, RUBIN RE: Autoantibodies to cryptic epitopes of C-reactive protein and other acute phase proteins in the toxic oil syndrome. J. Autoimmunity (1995) 8(2):293–303.
   PubMed Web of Science ®Google Scholar
• WATANABE-FUKUNAGA R, BRANNAN CI, COPELAND NG, JENKINS NA, NAGATA S: Lymphoproliferation disorder In mice explained by defects in Pas antigen that medi- ates apoptosis. Nature (1992) 356:314-317. One of the first descriptions of how a defect in apoptosis can lead to an autoimmune response.
   Google Scholar
• GLEICHMANN E, VAN ELVEN EH, VAN DER VEEN JPW: A systemic lupus erythematosus (SLE)-like disease in mice induced by abnormal T-B cell cooperation. Pref- erential formation of autoantlbociles characteristic of SLE. Eur. J. Immunol. (1982) 12:152–159.
   Google Scholar
• GLEICHMANN E, PALS WT, ROLINK AG, RADASZKIEWICZ T, GLEICHMANN H: Graft-versus-host reactions: clues tothe etiopathology of a spectrum of immunological diseases. Immunol. Today (1984) 5(11):324–332. One of the first descriptions of the similarities between the chronic graft-versus-host reaction and lupus.
   Google Scholar
• GOLDMAN M, DRUET P, GLEICHMANN E: Th2 cells in systemic autoimmunity: insites from allogeneic diseases and chemically-induced autoimmunity. Immunol. Today (1991) 12(7).223-227. One of the first descriptions of involvement of Th2 cells in autoim-munity.
   Google Scholar
• TOURNADE H, PELLETIER L, PASQUIER R et al.: Graft-ver-sus-host reactions in the rat mimic toxin-induced autoimmunity. din. Exp. Immunol. (1990) 81:334–338.
   PubMed Web of Science ®Google Scholar
• PRIGENT P, SAOUDI A, PANNETIER C et al.: Mercuric chloride, a chemical responsible for T cell (Th) 2-medi-ated autoimmunity in Brown Norway rats, directly triggers T cells to produce interleukin-4. J. Clin. Invest. (1995) 96:1484-1489. One of a series of mechanistic studies in an animal model of DIL.
   Google Scholar
• CORNACCHIA E, GOLBUS J, MAYBAUM J et al.: Hy- dralazine and procainamide inhibit T cell DNA methy-lation and induce autoreactivity. j Immunol. (1988) 140(7):2197–2200. First description of the connection between DNA methylation and DIL.
   Google Scholar
• YUNG RI, QUDDUS J, CRISP CE, JOHNSON KJ, RICHARD-SON BC: Mechanisms of drug-induced lupus: 1. cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J. Immunol. (1995) 154:3025-3035. Induction of autoimmunity in an animal model with lymphocytes in which DNA methylation had been inhibited by drugs.
   Google Scholar
• RICHARDSON B, SCHEINBART L, STRAHLER J et al.: Evi-dence for impaired Ted methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. (1990) 33:1665–1673.
   PubMed Web of Science ®Google Scholar
• YUNG RL, JOHNSON KJ, RICHARDSON BC: New concepts in the pathogenesis of drug-induced lupus. Lab. Invest.(1995) 73(6):746–759. Review of the possible connection of inhibition of DNA methylation and DIL.
   Google Scholar
• REZA MJ, DORNFELD L, GOLDBERG LS: Hydralazine ther-apy in hypertensive patients with idiopathic systemic lupus erythematosus. Arthritis Rheum. (1975) 18(4):335–338.
   PubMed Web of Science ®Google Scholar
• LAIRD PW, JACKSON-GRUSBY L, FAZELI A et at: Suppres-sion of intestinal neoplasia by DNA hypomethylation. Cell (1995) 81(2).197–205.
   PubMed Web of Science ®Google Scholar